Clinical trials: Disruptive Behaviors
Gambling Addiction, Gambling Disorder
The Effect of Self Stigma Tailored Cognitive Behavioral Therapy on Gambling Disorder
The goal of this clinical trial was to evaluate whether a cognitive behavioral therapy (CBT) program focused on self-stigma could help reduce both self-stigma and gambling disorder severity in adults diagnosed with gambling…
- Conditions
- Gambling Addiction, Gambling Disorder, Gambling Disorder Treatment, Stigma
- Trial name
- NCT06943963
- Testing
- Self Stigma Tailored Cognitive Behavioral Therapy on Gambling Disorder, standart pharmacotherapy, motivational intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Ege University
Pathological Gambling
Topiramate in the Treatment of Pathological Gambling
This study will assess the efficacy of topiramate in the treatment of pathological gambling. Pathological gambling (PG) is a debilitating disorder, generally leading to severe personal, familial, financial, social, and…
- Trial name
- NCT00245583
- Testing
- Topiramate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit/ Hyperactivity Disorder
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00714688
- Testing
- prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg
- Where
- 42 sites in Belgium, Denmark and 9 more
- Volunteers
- 279 people
- Sponsor
- Janssen-Cilag International NV
Pathological Gambling
Acamprosate in the Treatment of Pathological Gambling
The purpose of this study is to see whether acamprosate (Campral) will curb the desire to gamble in people with pathological gambling disorder.
- Trial name
- NCT00571103
- Testing
- acamprosate
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Attention Deficit Hyperactivity Disorder
Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
Background: Multiple studies have found Atomoxetine (Strattera) to be efficacious but there is only one published study specifically designed to evaluate its efficacy in school settings.
- Trial name
- NCT00918567
- Testing
- atomoxetine, Behavior Modification Therapy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- State University of New York at Buffalo
Attention-Deficit/Hyperactivity Disorder (ADHD)
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
The purpose of this study is to investigate the safety and efficacy of an investigational treatment for Attention Deficit Hyperactivity Disorder (ADHD) when compared to placebo.
- Trial name
- NCT00475735
- Testing
- MK0249, Concerta (methylphenidate)
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Hyperactivity Disorder
Development of a Multi-faceted Cognitive Training Program for Children With Attention Deficit Hyperactivity Disorder (ADHD)
After decades of Attention Deficit Hyperactivity Disorder (ADHD) intervention research, only two intervention approaches (i.e., psychopharmacology, behavioral treatment) have a "well-established" evidence-base supporting their…
- Trial name
- NCT01352468
- Testing
- Multifaceted cognitive training
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17
The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.
- Trial name
- NCT00150618
- Testing
- SPD503 (1 mg), SPD503 (2 mg), SPD503 (3 mg)
- Volunteers
- 324 people
- Sponsor
- Shire
ADHD, Sleep
Sleep IntervEntion as Symptom Treatment for ADHD
Up to 72% of adolescents with ADHD portray sleep problems. The most common sleep difficulties in adolescents with ADHD are initial insomnia, nocturnal awakenings, non-restorative or restless sleep.
- Conditions
- ADHD, Sleep, Adolescents, CBT
- Trial name
- SIESTA (NCT04723719)
- Testing
- SIESTA, Treatment as usual for ADHD
- Where
- Belgium
- Volunteers
- 92 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pathological Gambling
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.
- Trial name
- NCT01215357
- Testing
- Ecopipam
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Emalex Biosciences Inc.
Attention Deficit Hyperactivity Disorder
NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD
- Trial name
- NCT01654250
- Testing
- NWP09
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder (ADHD)
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12…
- Trial name
- NCT01835548
- Testing
- NT0102
- Where
- 4 sites in United States
- Volunteers
- 87 people
- Sponsor
- Neos Therapeutics, Inc
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and efficacy of Osmotic Release Oral System (OROS) methylphenidate in participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT01012622
- Testing
- Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
- Volunteers
- 142 people
- Sponsor
- Janssen Korea, Ltd., Korea
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01259492
- Testing
- Ritalin LA 20 mg, Ritalin LA 30 mg
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 725 people
- Sponsor
- Novartis Pharmaceuticals
ADHD
ADHD Treatment for Latino Families
The current pilot study aims to close the existing gap in our knowledge about effective psychosocial treatments for Latino families by providing preliminary data regarding the acceptability and efficacy of a culturally-modified…
- Trial name
- NCT02317692
- Testing
- Parent training
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Marquette University
Intermittent Explosive Disorder
A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder
This study will compare the medications fluoxetine (Prozac®) and divalproex (Depakote®) for the treatment of aggressive behavior in individuals with Intermittent Explosive Disorder (IED).
- Trial name
- NCT00078754
- Testing
- Fluoxetine, Divalproex
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
This is a randomized, double-blind, placebo-controlled, parallel-group study of NFC-1 versus placebo in adolescents with ADHD who have genetic disorders impacting mGluRs.
- Trial name
- NCT02777931
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Gambling, Tobacco Use Disorder
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent…
- Trial name
- NCT00967005
- Testing
- N Acetyl Cysteine, Sugar Pill
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Chicago
Trichotillomania, Skin-Picking
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors
The goal of the proposed study is to evaluate the efficacy and safety of dronabinol in trichotillomania and other body-focused repetitive behaviors such as skin-picking disorder.
- Trial name
- NCT03530800
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago